Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1546-1554, 2009. First published June 18, 2009; 10.1373/clinchem.2009.123620
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2009.123620v1
55/8/1546    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Hosono, N.
Right arrow Articles by Kubo, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosono, N.
Right arrow Articles by Kubo, M.
(Clinical Chemistry. 2009;55:1546-1554.)
© 2009 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection

Naoya Hosono1,a, Mamoru Kato2, Kazuma Kiyotani3, Taisei Mushiroda3, Sadaaki Takata1, Hiroko Sato1, Hanae Amitani1, Yumiko Tsuchiya1, Keiko Yamazaki1, Tatsuhiko Tsunoda2, Hitoshi Zembutsu4, Yusuke Nakamura1,4 and Michiaki Kubo1

1 Laboratory for Genotyping Development, 2 Laboratory for Medical Informatics, and 3 Laboratory for Pharmacogenetics, Center for Genomic Medicine, RIKEN, Yokohama, Japan; 4 Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, University of Tokyo, Tokyo, Japan.

aAddress correspondence to this author at: 1-7-22 Suehiro-cho, Tsurumi, Yokohama, Kanagawa, 230-0045, Japan. Fax +81-45-503-9606; e-mail nhosono{at}src.riken.jp.

Background: Cytochrome P450 2D6 (CYP2D6), one of the most important drug-metabolizing enzymes, has been reported to possess variation in the encoding CYP2D6 gene (cytochrome P450, family 2, subfamily D, polypeptide 6) that affects enzymatic activity. For the pharmacogenetic study of CYP2D6, accurate measurement of the dosage of the functional gene is essential; however, current genotyping techniques are insufficient because of their inability to provide the exact copy number of functional CYP2D6 genes.

Methods: We developed 3 quantitative real-time PCR (qPCR) assays for estimating the total copy number of the CYP2D6 gene, as well as 24-multiplex PCR-based real-time Invader assays (mPCR-RETINAs) for estimating the allele ratio at each variation locus. After determining the allele copy number at each locus, we estimated the frequencies of CYP2D6 alleles in a population and the diplotype in each individual by a CNVphaser (copy number variation phaser). The qPCR assays and RETINAs used for HapMap Japanese and Chinese samples were applied to 455 Japanese individuals.

Results: Forty-two individuals (9.2%) had one CYP2D6 gene copy, 207 (45.5%) had 2 copies, 161 (35.4%) had 3 copies, 40 (8.8%) had 4 copies, and 5 (1.1%) had 5 copies of the CYP2D6 gene. We found 16 different CYP2D6 alleles, with frequencies similar to those described in previous reports. In the diplotype analysis, we observed that CYP2D6*1/*1 and *1/*10-*36 were the most common diplotypes (approximately 20%) in our population.

Conclusions: Our method is the first to determine the exact number of functional CYP2D6 gene copies. We believe our method will facilitate and accelerate the detailed pharmacogenetic analysis of CYP2D6.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.